XML 67 R49.htm IDEA: XBRL DOCUMENT v3.25.1
Parent-Only Financial Statements (Tables) - Parent [Member]
 12 Months Ended
Dec. 31, 2024
Parent-Only Financial Statements (Tables) [Line Items]  
Schedule of Condensed Balance Sheets

The following represents condensed financial information of the parent company:

   As of December 31, 
   2023   2024 
   RMB   RMB   US$ 
ASSETS/(LIABILITIES)            
Cash and cash equivalents   1,205,993    2,227,649    309,895 
Prepayments   13,776    891    124 
Due from intercompany   456,041,568    814,547,651    113,314,180 
Investment in subsidiaries   (471,994,335)   (585,987,070)   (81,518,429)
TOTAL ASSETS (LIABILITIES)   (14,732,998)   230,789,121    32,105,770 
SHAREHOLDERS’ EQUITY (DEFICIT)               
Shareholders’ equity (deficit):               
Class A ordinary shares ($0.002 par value; 12,141,093 and 14,141,093 shares authorized as of December 31, 2023 and 2024, respectively; 4,192,730 and 13,273,596 shares issued as of December 31, 2023 and 2024, respectively; 3,724,236 and 12,815,143 shares outstanding as of December 31, 2023 and 2024, respectively)*   50,106    176,842    24,601 
Class B ordinary shares ($0.002 par value; 2,858,909 shares authorized; 2,858,909 shares issued and outstanding as of December 31, 2023 and 2024)*   36,894    36,894    5,132 
Additional paid-in capital   428,310,028    780,499,664    108,577,662 
Accumulated deficit   (452,031,693)   (565,218,741)   (78,629,283)
Statutory reserves   6,647,109    6,647,109    924,699 
Accumulated other comprehensive income   2,254,558    8,647,353    1,202,959 
TOTAL NANO LABS LTD SHAREHOLDERS’ EQUITY (DEFICIT)   (14,732,998)   230,789,121    32,105,770 

 

* After giving effect of the reverse stock splits, see Note 12.
Schedule of Condensed Statements of Operations and Comprehensive Income (Loss)
   For the years ended December 31, 
   2022   2023   2024 
   RMB   RMB   RMB   US$ 
Net revenues   
—
    
—
    
—
    
—
 
Operating expenses:                    
Selling and marketing expenses   
—
    
—
    
—
    
—
 
General and administrative expenses   5,822,906    471,664    683,178    95,039 
Total operating expenses   5,822,906    471,664    683,178    95,039 
Loss from operations   (5,822,906)   (471,664)   (683,178)   (95,039)
Finance income (expense)   66,144    110,971    (13,140)   (1,828)
Investment income   53,809    
—
    
—
    
—
 
Income (loss) from investment in subsidiaries   36,821,839    (252,463,079)   (112,490,730)   (15,648,925)
Net income (loss) attributable to Nano Labs Ltd   31,118,886    (252,823,772)   (113,187,048)   (15,745,792)
Comprehensive income (loss):                    
Net income (loss)   31,118,886    (252,823,772)   (113,187,048)   (15,745,792)
Other comprehensive income (loss)                    
Foreign currency translation adjustment   4,566,656    155,229    6,392,795    889,320 
Total comprehensive income (loss) attributable to Nano Labs Ltd   35,685,542    (252,668,543)   (106,794,253)   (14,856,472)
Schedule of Condensed Statements of Cash Flows
   For the years ended December 31, 
   2022   2023   2024 
   RMB   RMB   RMB   US$ 
Net cash provided by (used in) operating activities   3,911,561    344,012    (281,829)   (39,206)
Net cash used in investing activities   (155,900,936)   (68,918,960)   (312,142,434)   (43,423,075)
Net cash provided by financing activities   144,043,186    72,802,734    315,620,394    43,906,905 
Effect of exchange rate changes on cash and cash equivalents   7,883,387    (3,047,562)   (2,174,475)   (302,498)
Net increase (decrease) in cash and cash equivalents   (62,802)   1,180,224    1,021,656    142,126 
Cash and cash equivalents at beginning of the year   88,571    25,769    1,205,993    167,769 
Cash and cash equivalents at end of the year   25,769    1,205,993    2,227,649    309,895